Bisphosphonates: A review of their pharmacokinetic properties

Arie n̋s, 1977, Excursions in the field of SAR: a consideration of the past, the present and the future, 1

Arie n̋s, 1981, Optimalization of pharmacokinetics-An essential aspect of drug development, 165

Armstrong, 1984, Electrical phenomena and ion transport in the small intestine, Vol. 70, 309

Aurbach, 1988, Calcium-regulating hormones: parathyroid hormone and calcitonin, 43

Azuma, 1995, Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models, Bone, 16, 235, 10.1016/8756-3282(94)00035-X

Bijvoet, 1980, APD in Paget's disease of bone. Role of mononuclear phagocyte system?, Arth Rheum, 23, 1193, 10.1002/art.1780231018

Boulenc, 1993, Importance of the paracellular pathway for the transport of a new bisphosphate using the human Caco-2 monolayers model, Pharmacol Biochem, 46, 1591, 10.1016/0006-2952(93)90328-T

Chadwick, 1977, Measurements of intestinal permeability using low molecular weight polyethylene glycol (PEG 400) 1. Chemical analysis and biological properties of (PEG 400), Gastroenterology, 73, 241, 10.1016/S0016-5085(19)32196-1

Chadwick, 1977, Measurements of intestinal permeability using low molecular weight polyethylene glycos (PEG 400). 2. Application to normal and abnormal permeability states in man and animals, Gastroenterology, 73, 247, 10.1016/S0016-5085(19)32197-3

Conrad, 1981, Clodronate kinetics and dynamics, Clin Pharmacol Ther, 30, 114, 10.1038/clpt.1981.135

Daley-Yates, 1988, A comparison of the pharmacokinetics of 14C-labelled APD and 99m Tc-labelled ADP in the mouse, Calcif Tissue Int, 43, 125, 10.1007/BF02555158

Daley-Yates, 1992, Plasma protein binding of APD: Role of calcium and transferrin, Chem Biol Interact, 81, 79, 10.1016/0009-2797(92)90028-J

Daley-Yates, 1991, The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases, Calcif Tissue Int, 49, 433, 10.1007/BF02555856

Daley-Yates, 1989, Assay of 1-hydroxy-3-aminopropylidene-1, 1-bisphosphonate and related bisphosphonates in human urine and plasma by high performance ion chromatography, J Chromatogr, 490, 329, 10.1016/S0378-4347(00)82791-7

Eriksen, 1984, Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition, Metab Bone Dis Rel Res, 5, 243, 10.1016/0221-8747(84)90066-3

Eriksen, 1986, Kinetics of trabecular bone resorption and formation in hypothyroidism: evidence for a positive balance per remodeling cycle, Bone, 7, 101, 10.1016/8756-3282(86)90681-2

Eriksen, 1984, Trabecular bone remodeling and bone balance in hyperthyroidism, Bone, 6, 421, 10.1016/8756-3282(85)90218-2

Fitton, 1991, Pamidronate: a review of its pharmacological properties and therapeutic efficiency in resorptive bone disease, Drugs, 41, 289, 10.2165/00003495-199141020-00009

Fleisch, 1983, Bisphosphonates. Mechanism of action and clinical applications, 319

Fleisch, 1993, Bone and mineral metabolism, 8

Fleisch, 1979, Diphosphonates, Calcif Tissue Int, 27, 91, 10.1007/BF02441167

Fleisch, 1968, The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo, Calcif Tissue Res, 2, 10, 10.1007/BF02065192

Fleisch, 1969, Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo, Science, 165, 1262, 10.1126/science.165.3899.1262

Fleisch, 1970, Pyrophosphate and polyphosphate, 61

Fleisch, 1966, Effect of pyrophosphonate on hydroxyapatite and its implications in calcium homeostasis, Nature, 212, 901, 10.1038/212901a0

Flesch, 1989, Determination of the bisphosphonate pamidronate disodium in urine by pre-column derivatization with fluorescamine, highperformance liquid chromatography and fluorescence detection, J Chromatogr, 489, 446, 10.1016/S0378-4347(00)82928-X

Fogelman, 1986, Absorption of oral disphosphonates in normal subjects, Clin Endocrinol, 24, 57, 10.1111/j.1365-2265.1986.tb03254.x

Gertz, 1993, Clinical pharmacology of alendronate sodium, Osteopor Int, 3, 513

Gibaldi, 1982, Absorption kinetics and bioavailability, 145

Greven, 1981, Renal transport of drugs. Renal transport of organic substances, 1

Gural, 1985, Dosedependent absorption of disodium etidronate, J Pharm Pharmacol, 37, 443, 10.1111/j.2042-7158.1985.tb03035.x

Hanhijäri, 1989, Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days, Int J Clin Pharmacol Ther Toxicol, 27, 602

Henry, 1981, A model for the pH dependency of drug-protein binding, J Pharm Pharmacol, 33, 179, 10.1111/j.2042-7158.1981.tb13747.x

Hewitt, 1983, The renal excretion of drugs, Vol. 7, 11

Hu, 1992, Glucose effects on intestinal drug absorption: contributions of microclimate pH and paracellular pathway

Hyldstrup, 1993, Pharmacokinetic evaluation of pamidronate after oral administration: a study on dose proportionality, absolute bioavailability, and effect of repeated administration, Calcif Tissue Int, 53, 297, 10.1007/BF01351831

Janner, 1991, Sodium EDTA enhances intestinal absorption of two bisphosphonates, Calcif Tissue lot, 49, 280, 10.1007/BF02556218

Julio, 1975, Selective flame emission detection of phosphorus and sulfur in high-performance liquid chromatography, J Chromatogr, 112, 443, 10.1016/S0021-9673(00)99975-8

Jung, 1973, The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals, Calcif Tissue Res, 11, 269, 10.1007/BF02547227

Kahn, 1984, Structure-function relationships in bone: an examination of events at the cellular level, 125

Kasting, 1992, Retention of etidronate in human, dog and rat, J Bone Miner Res, 7, 513, 10.1002/jbmr.5650070507

Kline, 1992, Improved determination of the bisphosphonate alendronate in human plasma and urine by automated precolumn derivatization and high-performance liquid chromatography with fluorescence and electrochemical detection, J Chromatogr, 583, 183, 10.1016/0378-4347(92)80551-Z

Kragh-Hansen, 1973, Protein binding of small molecules I. Effect of pH and inorganic salts on the combination of phenol red with proteins, Biochem Biophys Acta, 295, 438

Lauren, 1991, Pharmacokinetics of clodronate after single intravenous, intramuscular and subcutaneous injections in rats, Pharmacol Toxicol, 69, 365, 10.1111/j.1600-0773.1991.tb01312.x

Leyvraz, 1992, Pharmacokinetics of pamidronate in patients with bone metastasis, J Nat Cancer Inst, 84, 788, 10.1093/jnci/84.10.788

Lin, 1992, Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats, Drug Metab Dispos, 20, 473

Lin, 1994, On the absorption of alendronate in rats, J Pharm Sci, 83, 1741, 10.1002/jps.2600831218

Lin, 1992, Renal handling of alendronate in rats. An uncharacterized renal transport system, Drug Metab Dispos, 20, 608

Lin, 1987, Protein binding as a primary determinant of clinical pharmacokinetic properties of non-steroidal antiinflammatory drugs, Clin Pharmacokin, 12, 402, 10.2165/00003088-198712060-00002

Lin, 1993, Uptake of alendronate by the bone tissues in hypocalcemic and hypercaleemic rats, Drug Metab Dispos, 21, 800

Lin, 1993, The role of calcium in plasma protein binding and renal handling of alendronate in hyper- and hypocalcemic rats, J Pharmacol Exp Ther, 267, 670

Lin, 1994, Nonlinear kinetics of alendronate: plasma protein binding and bone uptake, Drug Metab Dispos, 22, 400

Lin, 1989, Dose-dependent kinetics of cilastatin in laboratory animals, Drug Metab Dispos, 17, 426

Lin, 1988, Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and fsinopril in rats, Drug Metab Dispos, 16, 392

Lin, 1994, Dose-dependent pharmacokinetics: Experimental observation and theoretical consideration, Biopharm Drug Dispos, 15, 1, 10.1002/bdd.2510150102

Lin, 1991, Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals, Drug Metab Dispos, 19, 926

Lin, 1988, Kinetic studies on the competition between famotidine and cimelidine: evidence of multiple renal secretary systems for organic cations, Drug Metab Dispos, 16, 52

Meijer, 1983, Carrier-mediated transport in the handling of drugs by the liver, 167

Meijer, 1990, Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations, J Pharmacokin Biopharm, 18, 35, 10.1007/BF01063621

Michael, 1972, Metabolism of disodium ethane-1-hydroxy-1, 1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey, Toxicol Appl Pharmacol, 21, 503, 10.1016/0041-008X(72)90007-5

Mn̈kkönen, 1988, A one year follow-up study of the distribution of 14C-clodronate in mice and rats, Pharmacol Toxicol, 62, 51, 10.1111/j.1600-0773.1988.tb01843.x

Mönkkönen, 1989, Comparison of the distribution of three bisphosphonates in mice, Pharmacol Toxicol, 65, 294

Mönkkönen, 1987, Distribution of [14C]clodronate (dichloromethylene bisphosphonate) disodium in mice, Toxicol Appl Pharmacol, 89, 287, 10.1016/0041-008X(87)90050-0

Mönkkönen, 1990, The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice: The effects of vehicle and the route of administration, Eur J Drug Metab Pharmacokin, 15, 239, 10.1007/BF03190210

Mönkkönen, 1989, The uptake of clodronate (dichloromethylene bisphosphonate) by macrophages in vivo and in vitro, Drug Metab Dispos, 17, 690

Nielson, 1980, Interrelationships between calcium-phosphorous metabolism, serum parathyroid hormone and bone histomorphometry in non-dialyzed and dialyzed patients with chronic renal failure, Min Electrolyte Metab, 4, 113

Ostovic, D. and Brenner, G. S. Development of subcutaneous and intramuscular formulations of calcium alendronate salts. Pharm Res (in press).

Parfitt, 1988, Bone remodeling: relationship to the amount and structure of bone, and the pathogenesis and prevention of fractures, 45

Pedersen, 1971, Binding of calcium to serum albumin. I. Stoichiometry and intrinsic association constant at physiological pH, ionic strength and temperature, Scand J Clin Lab Invest, 28, 459, 10.3109/00365517109095724

Pedersen, 1972, Binding of calcium to serum albumin. II. Effect of pH via competitive hydrogen and calcium ion binding to the imidazole groups of albumin, Scand J Clin Lab Invest, 29, 75, 10.3109/00365517209081058

Pentikainen, 1989, Pharmacokinetics of clodronate in patients with metastatic breast cancer, Int J Clin Pharmacol Ther Toxicol, 27, 222

Powell, 1983, Clinical pharmacokinetics of diphosphonates, 41

Recker, 1973, Intestinal absorption of disodium ethane-1-hydroxyl-1-diphosphonate (disodium eidronate) using a deconvolution technique, Toxicol Appl Pharmacol, 24, 580, 10.1016/0041-008X(73)90219-6

Reitsma, 1983, Apposition and disposition of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD), Calcif Tissue Int, 35, 357, 10.1007/BF02405058

Reitsma, 1982, Differential actions of bisphosphonates on bone resorbing cells and the adjustment of skeletal metabolism

Rennick, 1981, Renal tubule transport of organic cations, Am J Physiol, 240, F83

Reynolds, 1972, The effect of two disphosphonates on the resorption of mouse calvaria in vitro, Calcif Tissue Res, 10, 302, 10.1007/BF02012561

Ruifrok, 1983, Paracellular transport of inorganic and organic ions across the rat ileum, Biochem Pharmacol, 32, 637, 10.1016/0006-2952(83)90487-2

Sahni, 1993, Bisphosphonates act on rat bone resorption through the mediation of osteoblasts, J Clin Invest, 91, 2004, 10.1172/JCI116422

Sato, 1991, Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure, J Clin Invest, 88, 2095, 10.1172/JCI115539

Schenk, 1986, Quantitative morphometric evaluation of inhibitory activity of new aminobisphosphonates on bone resorption in the rat, Calcif Tissue Int, 38, 342, 10.1007/BF02555748

Schultz, 1974, Ion transport by mammalian small intestine, Annu Rev Physiol, 36, 51, 10.1146/annurev.ph.36.030174.000411

Schuster, 1985, Renal clearance, Vol. 1, 365

Settle, 1971, The nature of drug-protein interaction, 175

Shinoda, 1983, Structure-activity relationships of various bisphosphonates, Calcif Tissue Int, 35, 87, 10.1007/BF02405012

Siegert, 1990, Blood flow evaluation of vascularized bone transfers in a canine model, J Orthop Res, 8, 291, 10.1002/jor.1100080219

Smith, 1971, Excretion of drugs in bile, Vol. XXVIII, 354

Szabo, 1978, The effect of fracture and blood loss on the medullary circulation, Magy Traumatol Orthop Helyreallito Sebesz, 21, 285

Troehler, 1975, Renal secretion of diphosphonates in rats, Kidney Int, 8, 6, 10.1038/ki.1975.70

Twiss, 1994, Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport, J Pharm Sci, 83, 699, 10.1002/jps.2600830521

Wiedmer, 1983, Ultrafiltrability and chromatographic properties of pyrophosphate, 1-hydroxyethylidene-1,1-bisphosphonate, and dichloromethylene-bisphosphonate in aqueous buffers and in human plasma, Calcif Tissue Int, 35, 397, 10.1007/BF02405066

Wilkinson, 1987, Clearance approaches in pharmacology, Pharmacol Rev, 39, 1

Wilson, 1989, Overview of epithelial barriers and drug transport, 11

Wilting, 1980, The effect of albumin conformation on the binding of warfarin to human serum albumin, J Biol Chem, 255, 3032, 10.1016/S0021-9258(19)85847-7

Wingen, 1987, Pharmacokinetics of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1,1-diphosphonic acid in mammals, ArzneimForsch/Drug Res, 37, 1037

Yakatan, 1982, Clodronate kinetics and bioavailability, Clin Pharmacol Ther, 31, 402, 10.1038/clpt.1982.51